亞輝龍(688575.SH):兩件專利分別榮獲第二十五屆中國專利銀獎、中國專利優秀獎
格隆匯6月8日丨亞輝龍(688575.SH)公佈,近日,國家知識產權局發佈了《關於第二十五屆中國專利獎授獎的決定》(國知發運字〔2025〕20 號),深圳市亞輝龍生物科技股份有限公司(以下簡稱"公司"或"亞輝龍")的"吖啶標記結合物及其製備方法、化學發光免疫檢測試劑盒"和"樣本分析儀的進樣裝置和樣本分析儀"兩件專利分別榮獲第二十五屆中國專利銀獎、中國專利優秀獎。相關專利具體信息如下:

亞輝龍此次獲得銀獎的專利技術是化學發光檢測試劑中的吖啶標記技術,獲得優秀獎的專利技術是分析儀的進樣結構和方法,均是公司研發人員在長期研發過程中不斷探索和創新的結晶。前述兩項技術不僅提高了產品的性能和品質,更為用户帶來了更加便捷、高效的使用體驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.